Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 8/20 | 0.44 |
| ▸ | LOX | P28300 | 5/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18249755 | 0.87 | LOXL2 (0.43) | LOXL2LOXTAAR1 | |
| SCHEMBL20239188 | 0.83 | DGAT2 (0.40) | LOXL2LOXDGAT2VNN1 | |
| SCHEMBL18249766 | 0.83 | PLAAT3 (0.44) | LOXL2LOXHDAC3HDAC1HDAC2 | |
| SCHEMBL20259122 | 0.83 | DGAT2 (0.45) | MAOBDGAT2VNN1TAAR1 | |
| Hydrochloric Acid SCHEMBL21924528 | 0.82 | LOXL2 (0.40) | LOXL2LOXDGAT2VNN1 | |
| Hydrochloric Acid SCHEMBL21924527 | 0.82 | LOXL2 (0.40) | LOXL2LOXDGAT2VNN1 | |
| SCHEMBL20239265 | 0.82 | DGAT2 (0.42) | LOXL2LOXDGAT2HDAC3HDAC1 | |
| SCHEMBL20239243 | 0.82 | DGAT2 (0.42) | LOXL2LOXDGAT2HDAC3HDAC1 | |
| SCHEMBL28655990 | 0.80 | LOXL2 (0.55) | LOXL2LOXMAOBTAAR1 | |
| SCHEMBL20259233 | 0.80 | LOX (0.45) | LOXL2LOXVNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107635975-B | DGAT2 inhibitors | 伊莱利利公司 | 2020-07-24 | — | — | CN | disclosed |
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | LOXL2 2081/4885LOX 2453/4885MAOB 2352/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | LOXL2 1951/4885LOX 2250/4885MAOB 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.